El interés en corto de BioCardia da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de BioCardia. Los datos de interés en corto se actualizan cada dos semanas.

BioCardia (NASDAQ:BCDA) Bolsa, Informe de interés en corto

BioCardia

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

BioCardia Inc

-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median Overall Survival of 18.4 months with Actimab-A + CLAG-M in patients with relapsed or refractory AML who received 1 or 2 lines of prior therapy
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mutation agnostic potential of Actimab-A demonstrated by high rates of Complete Remissions and Measurable Residual Disease Negativity in patients with high-risk features including TP53 mutations and prior Venetoclax treatment
-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Actimab-A + CLAG-M combination yielded deep and clinically meaningful responses with expected and manageable safety profile supporting planned pivotal Phase 2/3 trial
NEW YORK, March 17, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATNM#NYSE">ATNM</a>) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with relapsed/refractory acute myeloid leukemia (r/r AML) have been published in the peer-reviewed journal Leukemia. The publication highlights data including long-term survival outcomes from two-year follow-up and better outcomes in high-risk patients. Actimab-A is a novel targeted radiotherapeutic that uses the Actinium-225 (Ac-225) isotope payload directed against CD33, a marker expressed ubiquitously on AML blasts. The trial was conducted at the Medical College of Wisconsin (MCW) which has extensive experience treating relapsed refractory AML patients with CLAG-M.
Actimab-A + CLAG-M Trial Data Highlights from Publication:
<ul>
<li>18.4 month median Overall Survival (OS) in patients who received 1 or 2 lines of prior therapy</li>
<li>52% of patients in the Actimab-A +CLAG-M trial had TP53 mutations, 56% had prior allogeneic stem cell transplant and 56% of patients had prior Venetoclax therapy</li>
<li>Actimab-A + CLAG-M outcomes compare favorably to the results from historical data with CLAG-M alone in the pre-Venetoclax era from MCW's study (median OS of 13.3 months). Typically, patients who have failed Venetoclax treatment demonstrate median survival between 2.4 – 4.6 months as reported in the literature and the patients with a TP53 mutation even have more dismal survival outcomes. Hence this data supports the use of Actimab-A plus CLAG-M for these patients.</li>
<li>Actimab-A + CLAG-M produced high rates of measurable residual disease negativity (MRD-) including 75% across all patients, 83.3% in patients with a TP53 mutation and 100% in patients with prior Venetoclax therapy</li>
<li>71% of eligible patients received a bone marrow transplant (BMT) and median OS in these patients was 24.05 months</li>
</ul>

Biotech

News

General

ATNM

Actinium Pharmaceuticals Announces Publication Of Actimab-A + CLAG-M Trial Results In Patients With Relapsed Or Refractory Acute Myeloid Leukemia In The Peer-Reviewed Journal Leukemia

HC Wainwright &amp; Co. analyst Andrew Fein downgrades Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) from Buy to Neutral and lowers the price target from $12 to $2.

Downgrades

Price Target

Analyst Ratings

STRO

HC Wainwright & Co. Downgrades Sutro Biopharma to Neutral, Lowers Price Target to $2

WIIM

MGRM

Monogram Technologies shares are trading higher after the company received FDA clearance for the monogram mBôs TKA system.

Stifel analyst Nathan Jones maintains MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) with a Buy and lowers the price target from $17 to $16.

Stifel Maintains Buy on MRC Global, Lowers Price Target to $16

William Blair analyst Andrew Brackmann initiates coverage on Butterfly Network (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFLY#NYSE">BFLY</a>) with a Outperform rating.

Initiation

BFLY

William Blair Initiates Coverage On Butterfly Network with Outperform Rating

Alpha Modus, a leading innovator in AI-driven retail technology, today announced a groundbreaking settlement in its patent infringement lawsuit against Wakefern and Shelf Nine. As part of this resolution, Alpha Modus and Shelf Nine have reached a settlement agreement, while Shelf Nine's parent company, VSBLTY Groupe Technologies Corp. ("VSBLTY" or "VSBLTY Group Technologies"), and Alpha Modus negotiate a strategic partnership for the deployment of Alpha Modus' cutting-edge technology which would include a perpetual license for Alpha Modus' patented innovations.
The lawsuit—one of several filed by Alpha Modus against major retailers and digital signage networks, including Walgreens, Kroger, Wakefern, Shelf Nine, and Brookshire Grocery—centered on proprietary technology designed to enhance digital engagement and data-driven retail solutions. This agreement not only validates Alpha Modus' intellectual property rights but also establishes a long-term opportunity to integrate Alpha Modus' technology with VSBLTY's proprietary and robust data analytics software once VSBLTY Groupe Technologies and Alpha Modus finalize their strategic partnership agreement.

Legal

AMOD

Alpha Modus Settles Patent Infringement Suit With Wakefern And Shelf Nine; Negotiates Strategic Partnership With VSBLTY Group For Tech Deployment, Terms Not Disclosed

Needham analyst Mike Matson reiterates LivaNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIVN#NASDAQ">LIVN</a>) with a Buy and maintains $64 price target.

Reiteration

LIVN

Needham Reiterates Buy on LivaNova, Maintains $64 Price Target

NAOV

NanoVibronix shares are trading higher on possible continued strength after the company announced on Friday that it published its UroShield study, which showed positive data, including an 86% UTI reduction.

Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) has seen <a href="https://www.benzinga.com/quote/ANET/news">a recent pullback</a> with the stock down about 25% over the past month. But JPMorgan analyst Samik Chatterjee sees it as an opportunity rather than a red flag.
He's adding the stock to the firm&#8217;s Analyst Focus List, pointing to upside potential fueled by AI-driven Ethernet adoption in data centers. &#8220;Investors are overestimating the risks from Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and White Box competitors,&#8221;
Chatterjee stated, maintaining an Overweight rating with a $140 price target — implying a significant upside from current levels.
Arista stock closed the trading day, Friday, at $83.51 a share. That&#8217;s an upside of approximately 68%.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44218719/cisco-nvidia-arista-tackle-tariff-turmoil-whos-best-positioned">Cisco, Nvidia, Arista Tackle Tariff Turmoil: Who&#8217;s Best Positioned?</a>
<h2 class="wp-block-heading">Arista Stock: Pullback Presents A Buy Opportunity</h2>
According to Chatterjee, the recent decline in Arista stock stemmed from broader AI spending concerns among cloud customers and fears of competition from White Box companies. 
However, he argues that these worries are overstated. &#8220;Arista's AI-driven networking demand remains strong, and market fears are not aligned with long-term fundamentals,&#8221; he said. 
Trading at 28x 2026 consensus EPS, Arista stock isn&#8217;t cheap, but with earnings growth ahead and potential multiple expansion, the stock remains well-positioned for gains.
<h2 class="wp-block-heading">Valuation Retraces, But Growth Potential Remains</h2>
While Arista stock&#8217;s premium valuation reflected its high growth expectations, recent weakness has erased much of that premium. Currently trading at 33x next-twelve-month P/E, close to its historical average, Arista stock still offers room for appreciation as AI-related Ethernet adoption accelerates in 2026 and beyond. 
&#8220;We believe the stock&#8217;s premium valuation is justified given its dominant role in high-speed Ethernet switching for AI workloads,&#8221; Chatterjee noted.
<h2 class="wp-block-heading">Seasonal Weakness, But Second-Half Strength?</h2>
Historically, Arista stock underperforms in the first half of the year due to conservative guidance practices. However, the second half tends to see stronger performance, with guidance raises playing a key role. 
&#8220;Our confidence in Arista's second-half rebound remains high, particularly as AI-driven deployments ramp up,&#8221; Chatterjee said. 
Investors looking for AI-driven upside may find upcoming earnings reports to be the catalyst needed to reinforce confidence in the stock's trajectory.
<h2 class="wp-block-heading">Arista Vs. Nvidia: Market Share Concerns Overstated</h2>
A key question among investors is whether Nvidia's dominance in AI networking could hinder Arista's growth. Chatterjee pushes back against this concern, highlighting Arista's strong presence in front-end networks and ongoing market share gains. 
&#8220;While Nvidia dominates the AI accelerator market, Arista continues to win share in the Ethernet switching segment, which remains critical for AI infrastructure,&#8221; he explained. 
Despite some revenue moderation from Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) in early 2024, Arista remains a critical supplier for AI-driven data centers, positioning it well for future growth.
<h2 class="wp-block-heading">The White Box Question</h2>
White Box competitors have maintained a steady market share, but Arista's foothold with major cloud players remains strong. According to Chatterjee, White Box adoption outside top-tier cloud customers is limited due to software complexity, keeping Arista's competitive edge intact. 
&#8220;The software-driven differentiation Arista provides remains a key moat against commoditization,&#8221; he added.
With AI data centers shifting toward Ethernet adoption and Arista&#8217;s long-term growth intact, the current pullback presents an attractive entry point. 
&#8220;We see this as an opportunity for long-term investors, given Arista's clear path to AI infrastructure leadership,&#8221; Chatterjee concluded. As market concerns fade and earnings momentum builds, he sees a compelling case for Arista stock's continued outperformance.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/44005208/nvidia-ai-juggernaut-rolls-on-but-can-arista-cisco-keep-up">Nvidia Dominance Continues As AI Demand Grows: Can Arista, Cisco Keep Up?</a></li>
</ul>
Image: Shutterstock

Analyst Color

Long Ideas

Tech

Trading Ideas

ANET

NVDA

Arista Analyst Sees 68% Upside As Stock Pullback Presents Buying Opportunity

Protalix BioTherapeutics shares are trading higher after the company reported a FY 2024 GAAP EPS beat.

Truist Securities analyst Michael Lewis maintains Sila Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SILA#NYSE">SILA</a>) with a Buy and raises the price target from $27 to $28.

SILA

Truist Securities Maintains Buy on Sila Realty Trust, Raises Price Target to $28

U.S. retail sales showed a rebound in February following a sharp decline in January, yet the pace of the broader recovery fell short of economists&#8217; expectations, underscoring some challenges facing the American economy <a href="https://www.benzinga.com/news/econ-s">in the first quarter.</a>
Retail sales rose 0.2% month-over-month in February 2025, following a downwardly revised 1.2% contraction in January, according to advance estimates from the U.S. Census Bureau released Monday. The figure missed economist projections of a 0.6% increase, as tracked by TradingEconomics.
On an annual basis, retail sales grew 3.1%, slowing from the previous downwardly revised 3.9% growth.
Yet, key data in the report revealed underlying strength across major consumer categories. 
Non-store retailers, a key gauge of online sales, rose by 2.4% month-over-month and health and personal care stores soared by 1.7%. 
Excluding gas stations and auto sales, retail sales rose 0.5% month-over-month, rebounding from January&#8217;s 0.8% decline and outperforming expectations of a 0.4% gain.
The control group measure—which excludes sales from auto dealers, building materials, gas stations, office supply stores, mobile home dealers, and tobacco retailers—climbed 1% in February, fully offsetting January's 1% drop and vastly outperforming the expected 0.2% increase.
<h3 class="wp-block-heading">Market Reaction</h3>
U.S. stock futures rebounded following the retail trade report. As of 8:40 a.m. Eastern Time, S&amp;P 500 futures were down 0.1%, trimming earlier losses.. 
On Friday, the S&amp;P 500—tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)—closed 2.1% higher but still logged its fourth consecutive weekly loss.
Meanwhile, gold futures were up 0.3% extending their rally, after having closed their 10th positive week out of the last 11.
The U.S. dollar Index – a key measure of the greenback's strength – was down 0.1%.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/tech/25/03/44352209/gtc-2025-could-reignite-nvidias-stock-rally-but-only-if-b300-ai-server-roadmap-and-scaling-concerns-are-addressed-says-top-analyst">GTC 2025 Could Reignite Nvidia&#8217;s Stock Rally, But Only If B300, AI Server Roadmap, And Scaling Concerns Are Addressed, Says Top Analyst</a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

Retail Sales Rebound Less Than Expected In February: Online, Healthcare Spending Show Strong Gains

Truist Securities analyst Richard Newitter maintains Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) with a Buy and lowers the price target from $666 to $605.

ISRG

Truist Securities Maintains Buy on Intuitive Surgical, Lowers Price Target to $605

Harte-Hanks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HHS#NASDAQ">HHS</a>) reported quarterly losses of $(0.33) per share. This is a 22.22 percent decrease over losses of $(0.27) per share from the same period last year. The company reported $47.13 million in sales this quarter. This is a 4.77 percent decrease over sales of $49.49 million the same period last year.

Earnings

Harte-Hanks Q4 EPS $(0.33) Down From $(0.27) YoY, Sales $47.13M Down From $49.49M YoY

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) is a &#8220;meme&#8221; stock and that he doesn't need it because it&#8217;s losing <a href="https://www.benzinga.com/quote/SERV/earnings">too much money</a>.
The company reported weaker-than-expected fourth-quarter results. Adjusted EPS loss of 23 cents missed the consensus estimate for a loss of 18 cents.
&#8220;I'm kind of blown away about how badly the stock acts,&#8221; Cramer said when asked about The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>). &#8220;We get them on, maybe we can get some answers. Otherwise it's going to keep going down I'm afraid. &#8220;
As per the recent news, Trade Desk announced the appointment of Vivek Kundra as CEO, effective March 31.
Jim Cramer recommended buying Louisiana-Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPX#NYSE">LPX</a>) here.
On Feb. 19, Louisiana-Pacific reported fourth-quarter net sales growth of 3.5% year-over-year to $681 million, beating the consensus of $666.753 million.
Cramer said Enbridge Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) has &#8220;got so much business in America&#8221; and added that it's a great idea to buy the stock.
In the recent news, Enbridge named Steven W. Williams as chair of the board, effective May 7.
SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) is a &#8220;meme&#8221; stock, Cramer said.
The company announced it will participate in the 2025 Nvidia GPU Technology Conference.
The Mad Money host recommended buying Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>).
Accenture on Thursday announced a strategic investment in OPAQUE, a firm providing a secure AI platform designed to allow organizations to run large-scale, general-purpose AI workloads with encrypted data.
Price Action:
<ul>
<li>Serve Robotics shares jumped 9.1% to settle at $7.66 on Friday.</li>
<li>Trade Desk shares rose 0.1% to close at $53.94 during the session.</li>
<li>Louisiana-Pacific shares gained 2.4% to settle at $91.55.</li>
<li>Enbridge shares rose 0.7% to close at $42.83.</li>
<li>SoundHound AI shares jumped 16.1% to close at $10.34 on Friday.</li>
<li>Accenture shares gained 0.6% to settle at $318.82.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44326690/top-3-materials-stocks-that-may-collapse-in-march">Top 3 Materials Stocks That May Collapse In March</a></li>
</ul>
Photo: Shutterstock

Markets

Media

SERV

SOUN

Jim Cramer Calls This Stock A 'Meme Stock,' Recommends Buying Accenture

Truist Securities analyst Jake Bartlett maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Buy and raises the price target from $200 to $212.

Truist Securities Maintains Buy on Darden Restaurants, Raises Price Target to $212

ANTE

AirNet Technology shares are trading higher after the company announced the execution of a non-binding investment LOI with LLP STH Corp, a Kazakstan company.

Intel Corp&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) incoming CEO, Lip-Bu Tan, is planning a major overhaul of the company&#8217;s chip manufacturing and artificial intelligence operations, aiming to breathe new life into the struggling tech giant.
What Happened: Tan is considering significant changes to the company&#8217;s approach to AI and chip manufacturing. This includes staff cuts to address what he sees as a slow-moving and bloated middle management layer, according to a Reuters report on Monday.
Revamping the manufacturing operations, which once exclusively produced chips, but now also cater to external clients like Nvidia, is one of Tan&#8217;s key priorities.
Tan, who was previously a member of Intel&#8217;s board and&nbsp;CEO of chip design software&nbsp;firm Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) is poised to lead the company after a decade of setbacks under previous CEOs. These missteps led to Intel missing out on the booming demand for AI processors and smartphone chips, allowing competitors like Arm Holdings and Nvidia to dominate these markets.
Under Tan&#8217;s leadership, Intel is striving to enhance the performance of its manufacturing division, Intel Foundry, by actively securing new customers. The company also plans to restart the production of&nbsp;chips that drive AI servers&nbsp;and explore areas beyond servers, such as software, robotics, and AI foundation models.
SEE ALSO: <a href="https://www.benzinga.com/tech/25/03/44296708/ibm-ceo-arvind-krishna-says-deepseek-an-indicator-of-whats-to-come-predicts-ai-models-will-use-just-1-of-todays-energy-in-5-years">IBM CEO Arvind Krishna Says DeepSeek An Indicator Of What&#8217;s To Come, Predicts AI Models Will Use Just 1% Of Today&#8217;s Energy In 5 Years</a>
Why It Matters: Despite the ambitious plans, Tan&#8217;s strategy seems to be an enhancement of former CEO Pat Gelsinger&#8216;s turnaround plan, which sought to reshape Intel into a contract chip manufacturer. However, Gelsinger&#8217;s plan had to be scaled back due to cooling demand for Intel&#8217;s core products.
Tan&#8217;s appointment as CEO was announced on March 13, and it led to a surge in <a href="https://www.benzinga.com/markets/25/03/44297910/intel-stock-soars-nearly-12-in-thursday-pre-market-whats-going-on">Intel&#8217;s stock</a>. His incoming leadership and the proposed changes are seen as a potential turning point for Intel, which has been struggling to keep up with competitors in the rapidly evolving tech industry. In a town hall address held after his appointment, the CEO cautioned employees that the company will need to make &#8220;tough decisions.&#8221;
As Tan steps into his new role, the tech industry will be watching closely to see if his planned changes can turn around the fortunes of the ailing tech giant.
Intel stock has surged more than 18% over the past 5 days to close at $24.05 on Friday, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Intel holds a momentum rating of 31.37% and a growth rating of 80.60%, according to&nbsp;<a href="https://www.benzinga.com/report/INTC" target="_blank" rel="noreferrer noopener">Benzinga's Proprietary Edge Rankings</a>. The Benzinga Growth metric evaluates a stock&#8217;s historical earnings and revenue expansion across multiple timeframes, prioritizing both long-term trends and recent performance. For an in-depth report on more stocks and insights into growth opportunities,&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">sign</a>&nbsp;<a href="https://www.benzinga.com/screener/top-momentum-stocks" target="_blank" rel="noreferrer noopener">up for Benzinga Edge.</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="445" height="281" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17082207/image-139.png" alt="" class="wp-image-827199" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17082207/image-139.png 445w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/17082207/image-139-300x189.png 300w" sizes="(max-width: 445px) 100vw, 445px" /></figure>
READ MORE:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44352234/astrazeneca-seals-deal-for-esobiotec-to-advance-cell-therapy-details">AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

CDNS

INTC

Intel's New CEO Charts Revival Plan, Warns Of 'Tough Decisions' Ahead: Report

UBS analyst Brennan Hawken upgrades Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) from Neutral to Buy and maintains the price target from $180 to $180.

Upgrades

UBS Upgrades Blackstone to Buy, Maintains Price Target to $180

Truist Securities analyst Bertrand Donnes maintains BKV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKV#NYSE">BKV</a>) with a Buy and lowers the price target from $31 to $30.

Truist Securities Maintains Buy on BKV, Lowers Price Target to $30

Press Releases

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Health Care

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Comments

BioCardia

Interés en corto

BioCardia (NASDAQ:BCDA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL